Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 3/20 | 1.00 |
| ▸ | KDM4A | O75164 | 2/20 | 1.00 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 1.00 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 1.00 |
| ▸ | TET3 | O43151 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465914 | 1.00 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL7509 | 1.00 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL31620639 | 1.00 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL29844290 | 1.00 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL864236 | 1.00 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 | |
| Water SCHEMBL23358414 | 0.97 | TET2 (0.94) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL839512 | 0.97 | TET2 (0.94) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL20598827 | 0.97 | TET2 (0.94) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL19554357 | 0.97 | TET2 (0.94) | TET2KDM4AKDM4CKDM2ATET3 | |
| Lithium SCHEMBL31357194 | 0.97 | TET2 (0.94) | TET2KDM4AKDM4CKDM2ATET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 947 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534765-B2 | Methods and systems for noninvasive and localized brain liquid biopsy using focused ultrasound | WASHINGTON UNIVERSITY (US) | 2026-01-27 | — | — | US | claimed |
| US-20250314656-A1 | GENETICALLY ENCODED FLUORESCENT INDICATOR OF D-2-HYDROXYGLUTARATE | PRATT EVAN P S (US) | 2025-10-09 | — | — | US | claimed |
| EP-4611732-A1 | IDH MUTATIONS AS BIOMARKERS FOR ZOTIRACICLIB THERAPY | Li, Xiang (CN) | 2025-09-10 | — | — | EP | claimed |
| US-12310697-B2 | Methods and systems for noninvasive and localized brain liquid biopsy using focused ultrasound | WASHINGTON UNIVERSITY (US) | 2025-05-27 | — | — | US | claimed |
| US-12169202-B2 | Measurement of 2-hydroxyglutarate enantiomer levels as a biomarker for IDH mutant cancers | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-12-17 | — | — | US | claimed |
| US-20240344148-A1 | METHODS AND SYSTEMS FOR NONINVASIVE AND LOCALIZED BRAIN LIQUID BIOPSY USING FOCUSED ULTRASOUND | WASHINGTON UNIVERSITY | 2024-10-17 | — | — | US | claimed |
| US-12054788-B2 | Methods and systems for noninvasive and localized brain liquid biopsy using focused ultrasound | WASHINGTON UNIVERSITY (US) | 2024-08-06 | — | — | US | claimed |
| US-12042497-B2 | Methods of treating brain tumors using combination therapy | SERVIER PHARMACEUTICALS LLC (US) | 2024-07-23 | — | — | US | claimed |
| US-20240077423-A1 | A TRANSCRIPTIONAL REGULATOR SPECIFICALLY RESPONDING TO D-2-HYDROXYGLUTARATE AND APPLICATION THEREOF | SHANDONG UNIVERSITY (CN) | 2024-03-07 | — | — | US | claimed |
| WO-2024031406-A1 | IDH MUTATIONS AS BIOMARKERS FOR ZOTIRACICLIB THERAPY | LI XIANG (CN) | 2024-02-15 | — | — | WO | claimed |
| US-20140213580-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-31 | — | — | US | claimed |
| US-20140206673-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-24 | — | — | US | claimed |
| US-20140134667-A1 | Using Induced Pluripotent Stem Cells for Screening Anti-Neoplastic Agents | LIU SHI V (US) | 2014-05-15 | — | — | US | claimed |
| WO-2014062511-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | WO | claimed |
| EP-2721019-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2014-04-23 | — | — | EP | claimed |
| WO-2013130487-A2 | NOVEL OXIDOREDUCTASES FOR ENANTIOSELECTIVE REACTIONS | DUKE UNIVERSITY (US) | 2013-09-06 | — | — | WO | claimed |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | claimed |
| US-20130190249-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-25 | — | — | US | claimed |
| WO-2013102431-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | WO | claimed |
| WO-2012171337-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042497-B2 | Methods of treating brain tumors using combination therapy | MGMT, PYGB, VHL | TET2 2082/4885KDM4A 3125/4885KDM4C 2809/4885 |
| US-12534765-B2 | Methods and systems for noninvasive and localized brain liquid biopsy using focused ultrasound | FUS, HNRNPL, HNRNPU | TET2 3266/4885KDM4A 1782/4885KDM4C 2515/4885 |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | TET2 1901/4885KDM4A 3222/4885KDM4C 2228/4885 |
| US-20130190249-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | TET2 14/4885KDM4A 1101/4885KDM4C 475/4885 |
| US-20140206673-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | RNASE1, GZMB, ANXA2 | TET2 1488/4885KDM4A 3726/4885KDM4C 2426/4885 |
| US-20140213580-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | RNASE1, TP53, MCL1 | TET2 1949/4885KDM4A 4606/4885KDM4C 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.